News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Nomination Committee for the 2018 Annual General Meeting in PledPharma AB

October 25, 2017

PledPharma AB
Company Announcement

Nomination Committee for the 2018 Annual General Meeting in PledPharma AB

The Chairman of PledPharma AB has established a Nomination Committee for the
Annual General Meeting that is to be held on April 24, 2018. The Nomination
Committee is composed of members appointed by the four largest shareholders in
terms of voting rights, that have accepted the invitation to participate in the

The following members have been appointed by the four largest shareholders that
have accepted the invitation to participate in the Nomination Committee: 

Nortal Investments AB and Zimbrine Holding B.V.: Staffan Persson

Berinor B.V.: Peter Lindell

Flerie Participation AB: Thomas Eldered

Handelsbanken Fonder: Astrid Samuelsson

In total, the Nomination Committee represents 39,35% of the total number of
shares and votes in the company. 

The Nomination Committee has elected Staffan Persson as chairman for the
Committee. Håkan Åström (Chairman of PledPharma) has been co-opted to the
Nomination Committee. 

The Committee's assignment is to present to the Annual General Meeting
proposals regarding Chairman and other members of the board as well as
remuneration to the Board´s members. The Nomination Committee shall also submit
proposals for appointment and remuneration of auditors. Further, the Committee
shall submit proposals to the process to appoint the Nomination Committee for
the AGM in 2019. 

Shareholders who wish to submit proposals to the Nomination Committee can do so
by email: 

For more information please contact:

Håkan Åström, Chairman, phone: +46 703 747 213

Nicklas Westerholm, CEO, phone: +46 73 354 20 62

About PledPharma
PledPharma develops new drugs that protect the body against oxidative stress –
a potentially debilitating and sometimes life-threatening condition that can be
caused by chemotherapy treatment and following acetaminophen (paracetamol)
overdose. The company's most advanced project PledOx® is being developed to
reduce nerve damage associated with chemotherapy. A phase IIb study has been
conducted and will serve as the basis for the continued development. The drug
candidate Aladote® is being developed to reduce the risk of acute liver failure
associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on
Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel
+46 8 463 80 00). For more information, see



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10